Human and computational models of atopic dermatitis: A review and perspectives by an expert panel of the International Eczema Council.

Atopic dermatitis (AD) is a prevalent disease worldwide and is associated with systemic comorbidities representing a significant burden on patients, their families, and society. Therapeutic options for AD remain limited, in part because of a lack of well-characterized animal models. There has been increasing interest in developing experimental approaches to study the pathogenesis of human AD in vivo, in vitro, and in silico to better define pathophysiologic mechanisms and identify novel therapeutic targets and biomarkers that predict therapeutic response.

A randomized controlled study of combination therapy with alefacept and narrow band UVB phototherapy (UVB) for moderate to severe psoriasis: efficacy, onset, and duration of response.

Background: Alefacept is an effective intermittent treatment for psoriasis that can provide long-lasting remissions. Combination therapy with narrow-band ultraviolet B (nbUVB) phototherapy may enhance treatment outcomes and accelerate the onset of clinical response.

Objective: To assess the efficacy of alefacept in combination with nbUVB phototherapy compared to alefacept alone in subjects with moderate to severe psoriasis.

Large surface photodynamic therapy with aminolevulinic acid: treatment of actinic keratoses and beyond.

Photodynamic therapy (PDT) with topical aminolevulinic acid (ALA) is currently approved in the US and Canada for the spot treatment of non-hypertrophic actinic keratoses of the face and scalp. Dermatologists are currently using ALA-PDT on larger skin surfaces for the treatment of extensive actinic keratoses, sun damage P and acne. This article reviews the safety and efficacy of large surface ALA-PDT for the treatment of actinic keratoses and photodamage.